You are here

Recent Pfizer Press Releases

10/21/16 11:55am EDT
FDA Approves Supplemental New Drug Application for XTANDI® (enzalutamide) Capsules in Advanced Prostate Cancer

- TERRAIN Trial Showed Improved Radiographic Progression-Free Survival with Enzalutamide Versus Bicalutamide in Men with Metastatic Castration-Resistant Prostate Cancer -

Astellas Pharma Inc. (TSE: 4503) and Pfizer Inc.

10/19/16 6:02pm EDT
CDC Advisory Committee on Immunization Practices Votes to Recommend New Dosing Schedule for Vaccination with TRUMENBA® (Meningococcal Group B Vaccine)

Recommendation provides updated guidance for administering a two- or a three-dose series

Pfizer Inc. (NYSE: PFE) announced today that the U.S.

10/19/16 8:00am EDT
Pfizer Awarded Grant to Evaluate Vaccine to Protect Newborns Against Group B Streptococcus Infection

  • Grant from the Bill & Melinda Gates Foundation will help advance potential new vaccine that could provide protection from debilitating infections before and shortly after birth
  • About 1 out of every 4 pregnant women carries group B Streptococcus bacteriai which could be passed from mother to baby during labor and birth
  • A severe, aggressive and potentially deadly infection, group B Streptococcus is a leading cause of life-threatening neonatal sepsis and meningitisii

Pfizer Inc.

10/17/16 4:05pm EDT
Pfizer Announces The U.S. Availability Of Biosimilar INFLECTRA® (infliximab-dyyb)

Company to Begin Shipping to Wholesalers in Late November, 2016

Pfizer Inc.

10/15/16 10:30am EDT
Pfizer to Present New Data on XELJANZ® (Tofacitinib Citrate) for Ulcerative Colitis at UEG Week 2016

Pfizer Inc. (NYSE:PFE) announced that three abstracts for XELJANZ® (tofacitinib citrate), being investigated in moderate to severe ulcerative colitis (UC), will be presented at the upcoming United European Gastroenterology Week (UEG Week 2016), October 15-19 in Vienna, Austria.

10/10/16 2:15am EDT
First Positive Phase 3 Results In Adjuvant Setting For Renal Cell Carcinoma Show SUTENT® (sunitinib) Extended Disease Free Survival After Surgical Removal

Late-breaking data to be presented at the ESMO 2016 Congress and Published in The New England Journal of Medicine

Pfizer Inc.

10/9/16 10:30am EDT
Pfizer Presents Promising New Immunotherapy Combination Data With INLYTA® (axitinib) In Advanced Renal Cell Carcinoma (RCC)

  • Data From a Trial of INLYTA With Pembrolizumab Provides Additional Support for Novel Immunotherapy Combinations in RCC
  • Preliminary Results from an Ongoing Trial of INLYTA with Avelumab in RCC Were Also Presented

Pfizer Inc.

10/6/16 7:45am EDT
ICU Medical Inc. To Acquire The Hospira Infusion Systems Business From Pfizer Inc. For $1 Billion In Cash And Stock

The Addition of Hospira’s IV Pumps, Solutions, and Devices Business to ICU Medical’s Existing Portfolio Will Create a Leading Pure-Play Infusion Therapy Company
  • Creates an integrated pure-play infusion therapy company with focus and scale 
  • Combined business to compete in the US market with a unified organization and a complementary portfolio
  • Extends global reach for the combined company with direct operations in over 20 countries
  • Value-creating and risk mitigated deal structure
  • ICU Medical Inc. management conference call today at 8:00 am EST, details below


9/28/16 8:50am EDT
Pfizer Completes Acquisition of Medivation

  • Tender offer for all of the outstanding shares of Medivation common stock expired as scheduled one minute after 11:59 p.m., Eastern time, on September 27, 2016
  • Pfizer and Medivation begin joint operations on September 28, 2016
  • Combined expertise accelerates Pfizer’s leadership in Oncology, bringing much-needed new cancer treatments to patients
  • Expected to be immediately accretive to Pfizer’s Adjusted Diluted EPS upon closing, approximately $0.05 accretive in first full year after close with additional accretion and growth anticipated thereafter

Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Medivation, Inc.(NASDAQ: MDVN).

9/28/16 6:00am EDT
Pfizer to Showcase Progress of Broad-Based Oncology Portfolio at European Society for Medical Oncology (ESMO) 2016 Congress

20 abstracts across multiple tumor types; unique mechanisms of action address the diverse needs of people living with cancer

New combination study data in renal cell carcinoma and first-in-human results for OX40 agonist provide new insights in immuno-oncology

Pfizer Inc. (NYSE:PFE) today announced that it will be presenting data from 20 abstracts, including three late-breakers, at the European Society for Medical Oncology (ESMO) 2016 Congress in Copenhagen from October 7-11, 2016. The presentations demonstrate progress addressing cancer’s complex challenges through our work across 11 tumor types and eight distinct mechanisms of action, including two immuno-oncology/targeted therapy combination studies in renal cell carcinoma (RCC).

9/26/16 6:45am EDT
Pfizer Decides Remaining One Company Best Positions Company To Maximize Future Value Creation

  • Company to Continue to Operate as One Company with Two Distinct and Complementary Businesses to Retain Operating Strength and Financial Flexibility
  • Company Will Provide Enhanced Financial Transparency Beginning with First-Quarter 2017
  • Single-Company Structure Best Positions Pfizer to Deliver on Its Purpose to Deliver Medicines and Vaccines that Significantly Impact Patients’ Lives

Pfizer Inc. announced that, after an extensive evaluation, the company’s Board of Directors and Executive Leadership Team have determined the company is best positioned to maximize future shareholder value creation in its current structure and will not pursue splitting Pfizer Innovative Health and Pfizer Essential Health into two, separate publicly traded companies at this time.

9/23/16 8:30am EDT
Pfizer Announces Expiration of HSR Waiting Period For Proposed Acquisition of Medivation

Transaction expected to close in the Third-Quarter 2016

Pfizer Inc. (NYSE: PFE) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended has expired with respect to Pfizer’s pending acquisition of Medivation, Inc. (NASDAQ: MDVN).

Pfizer now expects to complete the acquisition in the Third-Quarter 2016. The closing of the tender offer remains subject to other customary closing conditions, including the tender of a majority of the outstanding shares of Medivation common stock.

About Pfizer:

9/22/16 11:56am EDT
Pfizer Declares 30-Cent Fourth-Quarter 2016 Dividend

The board of directors of Pfizer Inc. today declared a 30-cent fourth-quarter 2016 dividend on the company’s common stock, payable December 1, 2016, to shareholders of record at the close of business on November 11, 2016.

9/20/16 10:00am EDT
Pfizer Invites Public To View And Listen To Webcast Of November 1 Conference Call With Analysts

Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, November 1, 2016. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Third Quarter 2016 Performance Report, to be issued that morning.

9/16/16 5:24pm EDT
Pfizer Announces Positive Top-Line Results from REFLECTIONS B537-02 Study for PF-06438179 (infliximab-Pfizer) a Potential Biosimilar to Remicade® (infliximab)

Results confirm similar efficacy of PF-06438179 (infliximab-Pfizer) to Remicade® (infliximab), in combination with methotrexate

Pfizer Inc. (NYSE:PFE) announced the confirmatory study (REFLECTIONS B537-02) evaluating the efficacy, safety, and immunogenicity of PF-06438179 (infliximab-Pfizer) compared to Remicade® (infliximab) met its primary endpoint.

9/16/16 7:24am EDT
Pfizer Receives Positive CHMP Opinion For IBRANCE® (palbociclib) In Combination With Endocrine Therapy For The Treatment Of HR+/HER2- Metastatic Breast Cancer In Europe

Pfizer Inc. (NYSE:PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that IBRANCE® (palbociclib) be granted marketing authorization in the European Union (EU) for the treatment of women with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) locally advanced or metastatic breast cancer.

9/15/16 8:31am EDT
Merck and Pfizer Announce Investigational Ertugliflozin Met Primary Endpoint of A1C Reduction When Added to Sitagliptin and Metformin in People with Type 2 Diabetes

New Phase 3 Data Presented at the European Association for the Study of Diabetes Annual Meeting – Study Achieved Primary and All Key Secondary Endpoints

Merck (NYSE: MRK), known as MSD outside the United States and Canada, in partnership with Pfizer Inc. (NYSE: PFE) today announced that a Phase 3 study (VERTIS SITA2) of ertugliflozin, an investigational oral SGLT2 inhibitor for the treatment of patients with type 2 diabetes, met its primary endpoint.

9/14/16 6:14pm EDT
FDA Advisory Committees Recommend to Remove Boxed Warning in Labeling for Pfizer’s Smoking Cessation Therapy, CHANTIX® (varenicline)

Today, a joint meeting of the U.S. Food and Drug Administration’s (FDA) Psychopharmacologic Drugs Advisory Committee and Drug Safety Risk Management Advisory Committee reviewed data from EAGLES (Evaluating Adverse Events in a Global Smoking Cessation Study) evaluating the neuropsychiatric safety of CHANTIX® (varenicline). The Committees recommended by a majority vote to remove the boxed warning regarding serious neuropsychiatric adverse events from the CHANTIXlabeling.

9/13/16 10:00am EDT
Pfizer Launches New “Moodivator” App to Help Support, Encourage and Motivate People with Depression

Free App Helps Patients as They Manage their Condition through their iPhone with Easy-to-Use Features

Today, Pfizer Inc announced it has launched a new app, Moodivator, to help motivate and encourage the millions of adults who experience depression. Depression is one of the most common mental health disorders in the United States, as an estimated one in 15 adults (6.7%) experience at least one major depressive episode in any given year.

9/7/16 8:00am EDT
Pfizer Appoints Chief Scientific Officer for Neuroscience Research

Dr. Ole Isacson Brings World-renowned Expertise in Neurodegenerative Disease Research

Appointment and Additional Internal Promotions Solidify Cambridge, Mass. Scientific Leadership Team

Pfizer Inc. announced today that Dr. Ole Isacson, a world-renowned scientist and thought leader in neurology, will become Chief Scientific Officer of the Neuroscience Research Unit and Senior Vice President, effective September 16. Dr. Isacson is a Professor of Neurology at Harvard Medical School, and will continue to serve in an educational role. He is also a founding director of the Neuroregeneration Institute at McLean Hospital. Dr. Isacson will report directly to Mikael Dolsten, President of Worldwide Research and Development.